ArticleJournal of immunology (Baltimore, Md. : 1950)2009
Cutting Edge: Tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells.
Article in Journal of immunology (Baltimore, Md. : 1950), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 78 citations in OpenAlex.
- Decoding the Raf-Mek-Erk-Rsk pathway in prostate cancer: from molecular mechanisms to clinical opportunities.British journal of cancer · 2026Review
- Insights into the Mechanisms of Immune-Checkpoint Inhibitors Gained from Spatiotemporal Dynamics of the Tumor Microenvironment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Specific Polo-Like Kinase 1 Expression in Nodular Lymphocyte-Predominant Hodgkin Lymphoma Suggests an Intact Immune Surveillance Program.The American journal of pathology · 2024Article
- Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers.Molecular cancer · 2023Review
- Prostate Cancer Associated with Minimal Change Disease: A Case Report.Glomerular diseases · 2022Article
- Article
- [Research Status of Tumor-associated Fibroblasts Regulating Immune Cells].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022Review
- Targeting the spectrum of immune checkpoints in prostate cancer.Expert review of clinical pharmacology · 2021Review
- Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer.Prostate cancer and prostatic diseases · 2021Article
- Angiogenesis in Lymph Nodes Is a Critical Regulator of Immune Response and Lymphoma Growth.Frontiers in immunology · 2020Review
- Inducing Tumor Suppressive Microenvironments through Genome Edited CD47Scientific reports · 2019Article
- Low Expression of miR-424-3p is Highly Correlated with Clinical Failure in Prostate Cancer.Scientific reports · 2019Article
- Combined Photosensitization and Vaccination Enable CD8 T-Cell Immunity and Tumor Suppression Independent of CD4 T-Cell Help.Frontiers in immunology · 2019Article
- [Progress on cancer associated fibroblasts in tumor immunoregulation].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2018Review
- 5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy.Oncotarget · 2017Article
- Cellular determinants and microenvironmental regulation of prostate cancer metastasis.Seminars in cancer biology · 2017Review
- Bisphenol A Disrupts HNF4α-Regulated Gene Networks Linking to Prostate Preneoplasia and Immune Disruption in Noble Rats.Endocrinology · 2016Article
- Challenges and future perspectives of T cell immunotherapy in cancer.Immunology letters · 2015Review
- Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model.Journal of visualized experiments : JoVE · 2015Article
- Extending the lifespan and efficacies of immune cells used in adoptive transfer for cancer immunotherapies-A review.Oncoimmunology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
We previously reported that naive, tumor-specific CD8(+) (TcR-I) T cells transferred into prostate tumor-bearing mice traffic to the prostate where they become tolerized. We now report that TcR-I cells suppress the proliferation of naive T cells. This suppression is mediated at least in part by secreted factors, and the suppressive activity can be blocked by Abs directed against TGF-beta. We further report that TcR-I cells must infiltrate the prostate to acquire suppressive activity. Delivery of tumor-specific CD4(+) T cells prevents the conversion of TcR-I cells into suppressor cells. Taken together, our findings may have critical implications for sustaining T cell responsiveness during immunotherapy, as the development of suppressor cells in the tumor microenvironment may eliminate the potency of T cells primed in the periphery or delivered during adoptive immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.